Journal article
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- Abstract:
-
Summary
Expand abstract
Background: The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patients at high risk of disease progression. We report the final overall survival results of the trial. Methods: ICON7 was an international, phase 3, open-label, randomised trial undertaken at 263 centres in 11 countries across Europe, Canada, Aus...
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 389.7KB, Terms of use)
-
- Publisher copy:
- 10.1016/S1470-2045(15)00086-8
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet Oncology More from this journal
- Volume:
- 16
- Issue:
- 8
- Pages:
- 928-936
- Publication date:
- 2015-08-01
- DOI:
- ISSN:
-
1470-2045
- Pubs id:
-
pubs:571066
- UUID:
-
uuid:26460bac-70db-4bee-b0c3-edf9a568daab
- Local pid:
-
pubs:571066
- Source identifiers:
-
571066
- Deposit date:
-
2015-10-19
- ARK identifier:
Terms of use
- Copyright holder:
- Oza et al
- Copyright date:
- 2015
- Notes:
- Copyright © Oza et al. Open Access article distributed under the terms of CC BY. Open Access funded by Department of Health UK.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record